Skip to main content
Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery 1/2024

28.08.2023 | Original Article

Locally Advanced oral Squamous cell Carcinomas: Auditing and Outcome Appraisal

verfasst von: Rathindra Nath Bera, Richik Tripathi, Sapna Tandon, Mohd Adil, Sanober Sohail, Shashank, Avishek Chakraborty

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction: Patients with OSCC in India (oral squamous cell carcinoma) presents at a later stage with approximately 28% presenting at stage III and 64% at stage IV disease. In this retrospective study we have reviewed the treatment modalities rendered and outcomes associated for the management of locally advanced oral squamous cell carcinoma in our Institute. We evaluated the survival data and the factors effecting survival. Methods: Kaplan Meir method was used to evaluate OS and DFS rate and log rank test was used to compare the survival amongst groups. Cox regression analysis (univariate and multivariate) was used to evaluate the hazard ratio to find out the possible factors influencing risk of death and disease. Results: The median OS and DFS in our study were 32 and 24 months respectively. On a subset analysis of only T4b patients who underwent either upfront surgery or induction chemotherapy followed by surgery there was no significant difference in OS and DFS. All patients with TURD had partial response after induction chemotherapy and were subjected to surgical resection followed by adjuvant therapy. Conclusion: Extracapsular spread, bone involvement, skin infiltration, treatments, surgical margins and Lymph node size are the prime predictors of survival.Upfront surgery remains the standard of care for resectable LAOSCC. Induction chemotherapy might improve the resectability in technically unresectable OSCC. There is no difference in survival between concurrent chemoradiation, sequential chemoradiation and radical radiotherapy in the management of unresectable disease.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Alzahrani R, Obaid A, Al-Hakami H, Alshehri A, Al-Assaf H, Adas R et al (2020 Jan-Dec) Locally advanced oral cavity cancers: what is the Optimal Care? Cancer Control. 27(1):1073274820920727 Alzahrani R, Obaid A, Al-Hakami H, Alshehri A, Al-Assaf H, Adas R et al (2020 Jan-Dec) Locally advanced oral cavity cancers: what is the Optimal Care? Cancer Control. 27(1):1073274820920727
2.
Zurück zum Zitat Huang SH, O’Sullivan B (2017) Overview of the 8th Edition TNM classification for Head and Neck Cancer. Curr Treat Options Oncol 18(7):40CrossRefPubMed Huang SH, O’Sullivan B (2017) Overview of the 8th Edition TNM classification for Head and Neck Cancer. Curr Treat Options Oncol 18(7):40CrossRefPubMed
3.
4.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMed
5.
Zurück zum Zitat Dhar H, Vaish R, D’Cruz AK (2020) Management of locally advanced oral cancers. Oral Oncol 105:104662CrossRefPubMed Dhar H, Vaish R, D’Cruz AK (2020) Management of locally advanced oral cancers. Oral Oncol 105:104662CrossRefPubMed
6.
Zurück zum Zitat Mummudi N, Agarwal JP, Chatterjee S, Mallick I, Ghosh-Laskar S (2019) Oral Cavity Cancer in the Indian Subcontinent - Challenges and Opportunities. Clin Oncol (R Coll Radiol) 31(8):520–528CrossRefPubMed Mummudi N, Agarwal JP, Chatterjee S, Mallick I, Ghosh-Laskar S (2019) Oral Cavity Cancer in the Indian Subcontinent - Challenges and Opportunities. Clin Oncol (R Coll Radiol) 31(8):520–528CrossRefPubMed
7.
Zurück zum Zitat Gangopadhyay A, Bhatt S, Nandy K, Rai S, Rathod P, Puj KS (2021) Survival impact of Surgical Resection in locally advanced T4b oral squamous cell carcinoma. Laryngoscope 131(7):E2266–E2274CrossRefPubMed Gangopadhyay A, Bhatt S, Nandy K, Rai S, Rathod P, Puj KS (2021) Survival impact of Surgical Resection in locally advanced T4b oral squamous cell carcinoma. Laryngoscope 131(7):E2266–E2274CrossRefPubMed
9.
Zurück zum Zitat Yousem DM, Gad K, Tufano RP (2006 Nov-Dec) Resectability issues with head and neck cancer. AJNR Am J Neuroradiol 27(10):2024–2036 Yousem DM, Gad K, Tufano RP (2006 Nov-Dec) Resectability issues with head and neck cancer. AJNR Am J Neuroradiol 27(10):2024–2036
10.
Zurück zum Zitat Yousem DM, Hatabu H, Hurst RW et al (1995) Carotid artery invasion by head and neck masses: prediction with MR imaging. Radiology 195(3):715–720CrossRefPubMed Yousem DM, Hatabu H, Hurst RW et al (1995) Carotid artery invasion by head and neck masses: prediction with MR imaging. Radiology 195(3):715–720CrossRefPubMed
11.
Zurück zum Zitat Patil VM, Prabhash K, Noronha V et al (2014) Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers. Oral Oncol 50(10):1000–1004CrossRefPubMed Patil VM, Prabhash K, Noronha V et al (2014) Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers. Oral Oncol 50(10):1000–1004CrossRefPubMed
12.
Zurück zum Zitat Amin MB, Greene ES FL, et al (eds) (2017) AJCC Cancer Staging Manual, 8th edn. Springer International Publishing: American Joint Commission on Cancer;, New York Amin MB, Greene ES FL, et al (eds) (2017) AJCC Cancer Staging Manual, 8th edn. Springer International Publishing: American Joint Commission on Cancer;, New York
13.
Zurück zum Zitat Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10):843–850CrossRefPubMed Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10):843–850CrossRefPubMed
14.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed
15.
Zurück zum Zitat Spiotto MT, Jefferson G, Wenig B, Markiewicz M, Weichselbaum RR, Koshy M (2017) Differences in Survival with surgery and postoperative Radiotherapy compared with definitive chemoradiotherapy for oral cavity Cancer: a National Cancer Database Analysis. JAMA Otolaryngol Head Neck Surg 143(7):691–699CrossRefPubMedPubMedCentral Spiotto MT, Jefferson G, Wenig B, Markiewicz M, Weichselbaum RR, Koshy M (2017) Differences in Survival with surgery and postoperative Radiotherapy compared with definitive chemoradiotherapy for oral cavity Cancer: a National Cancer Database Analysis. JAMA Otolaryngol Head Neck Surg 143(7):691–699CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Sher DJ, Thotakura V, Balboni TA et al (2011) Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol 81(4):e215–e222CrossRef Sher DJ, Thotakura V, Balboni TA et al (2011) Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol 81(4):e215–e222CrossRef
17.
Zurück zum Zitat Gore SM, Crombie AK, Batstone MD, Clark JR (2015) Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma. Head Neck 37(4):518–523CrossRefPubMed Gore SM, Crombie AK, Batstone MD, Clark JR (2015) Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma. Head Neck 37(4):518–523CrossRefPubMed
18.
Zurück zum Zitat Licitra L, Grandi C, Guzzo M et al (2003) Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 21(2):327–333CrossRefPubMed Licitra L, Grandi C, Guzzo M et al (2003) Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 21(2):327–333CrossRefPubMed
19.
Zurück zum Zitat Zhong LP, Zhang CP, Ren GX et al (2013) Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 31(6):744–751CrossRefPubMed Zhong LP, Zhang CP, Ren GX et al (2013) Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 31(6):744–751CrossRefPubMed
20.
Zurück zum Zitat Marta GN, Riera R, Bossi P et al (2015) Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: systematic review and meta-analysis. Eur J Cancer 51(17):2596–2603CrossRefPubMed Marta GN, Riera R, Bossi P et al (2015) Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: systematic review and meta-analysis. Eur J Cancer 51(17):2596–2603CrossRefPubMed
21.
Zurück zum Zitat Liao CT, Ng SH, Chang JT, Wang HM, Hsueh C, Lee LY, Tsao CK, Chen WH, Chen IH, Kang CJ, Huang SF, Yen TC (2007) T4b oral cavity cancer below the mandibular notch is resectable with a favorable outcome. Oral Oncol 43(6):570–579CrossRefPubMed Liao CT, Ng SH, Chang JT, Wang HM, Hsueh C, Lee LY, Tsao CK, Chen WH, Chen IH, Kang CJ, Huang SF, Yen TC (2007) T4b oral cavity cancer below the mandibular notch is resectable with a favorable outcome. Oral Oncol 43(6):570–579CrossRefPubMed
22.
Zurück zum Zitat Kumar A, Singh R, Santhosh M et al (2021) Role of structures in the masticator space in selecting patients with resectable T4b oral cancer: findings from a survival analysis. Int J Oral Maxillofac Surg 50(5):579–584CrossRefPubMed Kumar A, Singh R, Santhosh M et al (2021) Role of structures in the masticator space in selecting patients with resectable T4b oral cancer: findings from a survival analysis. Int J Oral Maxillofac Surg 50(5):579–584CrossRefPubMed
23.
Zurück zum Zitat Patil VM, Noronha V, Joshi A et al (2013 Jan-Mar) Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: does it make a difference? Indian J Cancer 50(1):1–8 Patil VM, Noronha V, Joshi A et al (2013 Jan-Mar) Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: does it make a difference? Indian J Cancer 50(1):1–8
24.
Zurück zum Zitat oshi A, Patil VM, Noronha V, Juvekar S, Deshmukh A, Chatturvedi P, Chaukar DA, Agarwal JP, Ghosh S, Murthy V, D’cruz A, Prabhash K (2013 Oct-Dec) Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers? Indian J Cancer 50(4):349–355 oshi A, Patil VM, Noronha V, Juvekar S, Deshmukh A, Chatturvedi P, Chaukar DA, Agarwal JP, Ghosh S, Murthy V, D’cruz A, Prabhash K (2013 Oct-Dec) Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers? Indian J Cancer 50(4):349–355
25.
Zurück zum Zitat Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21(1):92–98CrossRefPubMed Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21(1):92–98CrossRefPubMed
26.
Zurück zum Zitat Foster CC, Melotek JM, Brisson RJ et al (2018) Definitive chemoradiation for locally-advanced oral cavity cancer: a 20-year experience. Oral Oncol 80:16–22CrossRefPubMed Foster CC, Melotek JM, Brisson RJ et al (2018) Definitive chemoradiation for locally-advanced oral cavity cancer: a 20-year experience. Oral Oncol 80:16–22CrossRefPubMed
28.
Zurück zum Zitat Haddad R, O’Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264CrossRefPubMed Haddad R, O’Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264CrossRefPubMed
29.
Zurück zum Zitat Cohen EEW, Karrison TG, Kocherginsky M et al (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 32(25):2735–2743CrossRefPubMedPubMedCentral Cohen EEW, Karrison TG, Kocherginsky M et al (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 32(25):2735–2743CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Hitt R, López-Pousa A, Martínez-Trufero J et al (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23(34):8636–8645CrossRefPubMed Hitt R, López-Pousa A, Martínez-Trufero J et al (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23(34):8636–8645CrossRefPubMed
31.
Zurück zum Zitat Hitt R, Grau JJ, López-Pousa A et al (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25(1):216–225CrossRefPubMed Hitt R, Grau JJ, López-Pousa A et al (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25(1):216–225CrossRefPubMed
32.
Zurück zum Zitat Ghi M, Paccagnella A, Ferrari D et al (2017) Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol 28(9):2206–2212CrossRefPubMed Ghi M, Paccagnella A, Ferrari D et al (2017) Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol 28(9):2206–2212CrossRefPubMed
33.
Zurück zum Zitat Lacas B, Carmel A, Landais C, MACH-NC Collaborative Group et al (2021) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol 156:281–293CrossRefPubMedPubMedCentral Lacas B, Carmel A, Landais C, MACH-NC Collaborative Group et al (2021) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol 156:281–293CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Lacas B, Bourhis J, Overgaard J, MARCH Collaborative Group et al (2017) Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol 18(9):1221–1237CrossRefPubMedPubMedCentral Lacas B, Bourhis J, Overgaard J, MARCH Collaborative Group et al (2017) Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol 18(9):1221–1237CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Petit C, Lacas B, Pignon JP, MACH-NC, Collaborative Groups MARCH (2021) Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol 22(5):727–736CrossRefPubMed Petit C, Lacas B, Pignon JP, MACH-NC, Collaborative Groups MARCH (2021) Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol 22(5):727–736CrossRefPubMed
Metadaten
Titel
Locally Advanced oral Squamous cell Carcinomas: Auditing and Outcome Appraisal
verfasst von
Rathindra Nath Bera
Richik Tripathi
Sapna Tandon
Mohd Adil
Sanober Sohail
Shashank
Avishek Chakraborty
Publikationsdatum
28.08.2023
Verlag
Springer India
Erschienen in
Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe 1/2024
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-023-04168-4

Weitere Artikel der Ausgabe 1/2024

Indian Journal of Otolaryngology and Head & Neck Surgery 1/2024 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.